Alopecia Induced by CDK 4/6 Inhibitors and Its Impact on the Quality of Life of Patients with Advanced Breast Cancer
November 2025
Studysummary This study found that 49% of female breast cancer patients treated with CDK4/6 inhibitors for at least three months developed alopecia, which significantly impacted their quality of life, with greater alopecia severity leading to worse emotional and functional well-being.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on researchsquare.com →